---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-025817"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T15:09:10.891567+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics issues $750K convertible note to Keystone Capital with conversion price floor at $0.05

## Summary
- Issued convertible promissory note to Keystone Capital Partners; purchase price $750,000, principal face value $937,500.
- Note bears 10% interest, matures August 6, 2027; conversion price is lesser of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.
- Beneficial ownership limitation of 4.99%; company must file registration statement for resale of conversion shares.
- Offered under Section 4(a)(2) and Rule 506(b) exemption; no public offering.
- Maximum aggregate borrowing up to $1,000,000 under the note.

## SEC filing metadata
- accession: 0001213900-26-025817
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/ea0280905-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-025817
- JSON: https://secwatch.observer/filing/0001213900-26-025817.json
- Plain text: https://secwatch.observer/filing/0001213900-26-025817.txt

## Key facts
- Debt Financings
  CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $750,000 purchase price, $937,500 principal face value, up to $1,000,000 aggregate with Keystone Capital Partners, LLC at 10% per annum maturing August 6, 2027.
  - Instrument: convertible notes
  - Principal: $750,000 purchase price, $937,500 principal face value, up to $1,000,000 aggregate
  - Counterparty: Keystone Capital Partners, LLC
  - Rate: 10% per annum
  - Maturity: August 6, 2027
  - Event: incurrence
  source text: On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm
- Equity Issuances
  CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for purchase price of $750,000.
  - Security: convertible note
  - Purchaser: Keystone Capital Partners, LLC
  - Consideration: purchase price of $750,000
  source text: On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. entered into Convertible Promissory Note with Keystone Capital Partners, LLC valued at Purchase price $750,000; principal face value $937,500; maximum aggregate borrowings $1,000,000; int (effective 2026-03-06).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: Keystone Capital Partners, LLC
  - Value: Purchase price $750,000; principal face value $937,500; maximum aggregate borrowings $1,000,000; int
  - Effective: 2026-03-06
  source text: On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.